SlideShare uma empresa Scribd logo
1 de 9
Solutions for proteins Information provided in this presentation is proprietary and shall not be distributed without the prior written consent of Soluble Therapeutics, LLC
HSC TM   Technology ,[object Object],[object Object],Correlated to crystallization and solubility. B Value Measurements Proteins in Crystal Conditions
HSC TM   Technology Rapid screening of the influence of additives on protein-protein interaction.
HSC TM   Technology Syringe Pump Injector HSC Instrument UV Detector To Waste
 
 
Case Study: Improving the solubility of Osteoprotegerin using the HSC Technology 1 11 50 Formulation Contents Solubility (mg/ml) Original 20mM HEPES pH 7, 10mM NaCl, 1mM TCEP HSC (Initial and Discovery) 50mM HEPES pH 7, 0.2M NaCl, 10% Glycerol, 0.15M Trehalose, 1mM TCEP HSC + ANN (Formulation) 0.1M MES pH 6.1, 0.8M LiCl, 0.1M Glycine, 15% MPD
Benefits of the HSC TM   Technology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Contacts Email:  [email_address] Phone: 205-420-2055 Information provided in this presentation is proprietary and shall not be distributed without the prior written consent of Soluble Therapeutics, LLC

Mais conteúdo relacionado

Semelhante a HSC Technology - Solutions For Proteins

Drug metabolism and toxicity 2013
Drug metabolism and toxicity 2013Drug metabolism and toxicity 2013
Drug metabolism and toxicity 2013
Elsa von Licy
 
Paracetamol_Paper Published_Aug 2015
Paracetamol_Paper Published_Aug 2015Paracetamol_Paper Published_Aug 2015
Paracetamol_Paper Published_Aug 2015
Mohan Thippeswamy
 
Bioanalytical method development and validation of azilsartan medoxomil potas...
Bioanalytical method development and validation of azilsartan medoxomil potas...Bioanalytical method development and validation of azilsartan medoxomil potas...
Bioanalytical method development and validation of azilsartan medoxomil potas...
BRNSSPublicationHubI
 
Bioanalytical Method Development and Validation for Simultaneous Estimation o...
Bioanalytical Method Development and Validation for Simultaneous Estimation o...Bioanalytical Method Development and Validation for Simultaneous Estimation o...
Bioanalytical Method Development and Validation for Simultaneous Estimation o...
BRNSSPublicationHubI
 
Lusk_ceftriaxone_ASMS_2016_23May16
Lusk_ceftriaxone_ASMS_2016_23May16Lusk_ceftriaxone_ASMS_2016_23May16
Lusk_ceftriaxone_ASMS_2016_23May16
Todd Lusk
 
method development and validation
method development and validationmethod development and validation
method development and validation
NITIN KANWALE
 

Semelhante a HSC Technology - Solutions For Proteins (20)

Method Validation: Comparison among two analitical methods for the determinat...
Method Validation: Comparison among two analitical methods for the determinat...Method Validation: Comparison among two analitical methods for the determinat...
Method Validation: Comparison among two analitical methods for the determinat...
 
Pharmaceutical Biotechnology Research Presentation : Recombinant Streptokinase
Pharmaceutical Biotechnology Research Presentation : Recombinant StreptokinasePharmaceutical Biotechnology Research Presentation : Recombinant Streptokinase
Pharmaceutical Biotechnology Research Presentation : Recombinant Streptokinase
 
Discovery and Analysis of Peanut Allergens using Proteomic approaches with Io...
Discovery and Analysis of Peanut Allergens using Proteomic approaches with Io...Discovery and Analysis of Peanut Allergens using Proteomic approaches with Io...
Discovery and Analysis of Peanut Allergens using Proteomic approaches with Io...
 
Drug metabolism and toxicity 2013
Drug metabolism and toxicity 2013Drug metabolism and toxicity 2013
Drug metabolism and toxicity 2013
 
Direct Peptide Reactivity Assay(DPRA)
Direct Peptide Reactivity Assay(DPRA)Direct Peptide Reactivity Assay(DPRA)
Direct Peptide Reactivity Assay(DPRA)
 
Symposium presentation: Development of a Dried Blood Spot Method for Leptin
Symposium presentation:  Development of a Dried Blood Spot Method for LeptinSymposium presentation:  Development of a Dried Blood Spot Method for Leptin
Symposium presentation: Development of a Dried Blood Spot Method for Leptin
 
Paracetamol_Paper Published_Aug 2015
Paracetamol_Paper Published_Aug 2015Paracetamol_Paper Published_Aug 2015
Paracetamol_Paper Published_Aug 2015
 
Bioanalytical method development and validation of azilsartan medoxomil potas...
Bioanalytical method development and validation of azilsartan medoxomil potas...Bioanalytical method development and validation of azilsartan medoxomil potas...
Bioanalytical method development and validation of azilsartan medoxomil potas...
 
Analysis of Body Fluids using Mass spectroscopy.pptx
Analysis of Body Fluids using Mass spectroscopy.pptxAnalysis of Body Fluids using Mass spectroscopy.pptx
Analysis of Body Fluids using Mass spectroscopy.pptx
 
Bioanalytical Method Development and Validation for Simultaneous Estimation o...
Bioanalytical Method Development and Validation for Simultaneous Estimation o...Bioanalytical Method Development and Validation for Simultaneous Estimation o...
Bioanalytical Method Development and Validation for Simultaneous Estimation o...
 
Analytical method development and validation
Analytical method development and validationAnalytical method development and validation
Analytical method development and validation
 
Application of chromatography in pharmaceutics
Application of chromatography in pharmaceuticsApplication of chromatography in pharmaceutics
Application of chromatography in pharmaceutics
 
Enabling Cancer Immunotherapy: From Discovery to Combinations
Enabling Cancer Immunotherapy: From Discovery to CombinationsEnabling Cancer Immunotherapy: From Discovery to Combinations
Enabling Cancer Immunotherapy: From Discovery to Combinations
 
Protein gen
Protein genProtein gen
Protein gen
 
Journal Combinatorial Chemistry 2006 v8 p820
Journal Combinatorial Chemistry 2006 v8 p820Journal Combinatorial Chemistry 2006 v8 p820
Journal Combinatorial Chemistry 2006 v8 p820
 
Lusk_ceftriaxone_ASMS_2016_23May16
Lusk_ceftriaxone_ASMS_2016_23May16Lusk_ceftriaxone_ASMS_2016_23May16
Lusk_ceftriaxone_ASMS_2016_23May16
 
Er Pr
Er PrEr Pr
Er Pr
 
Accelrys UGM slides 2011
Accelrys UGM slides 2011Accelrys UGM slides 2011
Accelrys UGM slides 2011
 
Haemolysis effect of Mefenamic Acid 250 mg Capsule in Bio analysis by liquid ...
Haemolysis effect of Mefenamic Acid 250 mg Capsule in Bio analysis by liquid ...Haemolysis effect of Mefenamic Acid 250 mg Capsule in Bio analysis by liquid ...
Haemolysis effect of Mefenamic Acid 250 mg Capsule in Bio analysis by liquid ...
 
method development and validation
method development and validationmethod development and validation
method development and validation
 

Último

Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Safe Software
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Safe Software
 
Architecting Cloud Native Applications
Architecting Cloud Native ApplicationsArchitecting Cloud Native Applications
Architecting Cloud Native Applications
WSO2
 
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Victor Rentea
 
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Victor Rentea
 

Último (20)

Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
 
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
 
MS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectorsMS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectors
 
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
 
Rising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdf
Rising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdfRising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdf
Rising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdf
 
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
 
Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...
 
WSO2's API Vision: Unifying Control, Empowering Developers
WSO2's API Vision: Unifying Control, Empowering DevelopersWSO2's API Vision: Unifying Control, Empowering Developers
WSO2's API Vision: Unifying Control, Empowering Developers
 
Six Myths about Ontologies: The Basics of Formal Ontology
Six Myths about Ontologies: The Basics of Formal OntologySix Myths about Ontologies: The Basics of Formal Ontology
Six Myths about Ontologies: The Basics of Formal Ontology
 
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
 
Architecting Cloud Native Applications
Architecting Cloud Native ApplicationsArchitecting Cloud Native Applications
Architecting Cloud Native Applications
 
AWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of Terraform
 
presentation ICT roal in 21st century education
presentation ICT roal in 21st century educationpresentation ICT roal in 21st century education
presentation ICT roal in 21st century education
 
ICT role in 21st century education and its challenges
ICT role in 21st century education and its challengesICT role in 21st century education and its challenges
ICT role in 21st century education and its challenges
 
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
 
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
 
How to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected WorkerHow to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected Worker
 
Artificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : UncertaintyArtificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : Uncertainty
 

HSC Technology - Solutions For Proteins

  • 1. Solutions for proteins Information provided in this presentation is proprietary and shall not be distributed without the prior written consent of Soluble Therapeutics, LLC
  • 2.
  • 3. HSC TM Technology Rapid screening of the influence of additives on protein-protein interaction.
  • 4. HSC TM Technology Syringe Pump Injector HSC Instrument UV Detector To Waste
  • 5.  
  • 6.  
  • 7. Case Study: Improving the solubility of Osteoprotegerin using the HSC Technology 1 11 50 Formulation Contents Solubility (mg/ml) Original 20mM HEPES pH 7, 10mM NaCl, 1mM TCEP HSC (Initial and Discovery) 50mM HEPES pH 7, 0.2M NaCl, 10% Glycerol, 0.15M Trehalose, 1mM TCEP HSC + ANN (Formulation) 0.1M MES pH 6.1, 0.8M LiCl, 0.1M Glycine, 15% MPD
  • 8.
  • 9. Contacts Email: [email_address] Phone: 205-420-2055 Information provided in this presentation is proprietary and shall not be distributed without the prior written consent of Soluble Therapeutics, LLC

Notas do Editor

  1. This presentation will introduce you to the HSC technology, it’s power, and how it can be used to achieve your research and development goals.
  2. The solublization and stabilization of formulated protein solutions and the crystallization of proteins are inextricably linked to the thermodynamics of protein interactions. The HSC technology is used to quantitatively measure protein-protein interactions. These interactions are calculated as the second virial coefficient, or B value, which is the sum of all potential forces between two proteins. -Positive B values indicate net repulsion -whereas negative B values indicate net attraction. Additives can be introduced to solutions, which can alter the B value so that the a protein displays mild attraction conducive to crystallization. Alternatively, additives can be used to enhance repulsion thereby increasing the protein’s solubility and physical stability.
  3. This image shows the HSC Instrument used to calculate the B values of proteins in solution. It has two components. On the left is the high-throughput instrument where the target protein and additives are analyzed and on the right is the computer used to capture the raw data required to calculate the B values. In approximately 3 weeks, all of this information is compiled and stored for subsequent processing by the artificial neural network.
  4. This illustration depicts how the HSC technology derives the B values from the interactions of the customer’s target protein. A small amount of the customer’s protein is bound to the matrix of a column within the HSC Instrument. Proteins in solution with one of 40 additives at either a high or low concentration are then injected into the column and allowed to pass over the bound protein. A UV detector is used to establish the flow through speed. The flow through speed, in addition to a number of molecular parameters, is an input to an equation that allows the high-throughput system to automatically calculate a B value. However, generally speaking, a slower flow through speed indicates greater protein-protein interaction and thus a more negative B value. Conversely, a faster flow through speed indicates less interaction and thus a more positive B value.
  5. For ease of understanding and to best serve our customers, we offer our services as three screening options. Once the protein has been received and its condition confirmed, the initial screen is performed. During the initial screen, the HSC Instrument is used by our highly experienced staff to determine the B values of your protein in combination with 40 different additives in 80 conditions. The discovery screen then expands upon the conditions of the 9 most promising additives identified from the initial screen. The data derived from the initial and discovery screens combined with data derived from calorimetry assays are analyzed by an artificial neural network as part of the formulation screen.
  6. The artificial neural network, depicted here, provides a powerful companion analysis and predictive capability to the high-throughput component of the HSC technology. It uses the data generated from the 161 assays performed in the initial and discovery screens combined with the algorithms’ predictive components to generate in silico B values for more than 12,000 formulations. It is important to point out that this entire process, including the initial, discovery, and formulation screens takes about one month to complete.
  7. In this example, performed with an inherently insoluble protein, osteoprotegerin, the maximum original concentration of 1 mg/ml was ultimately increased to 50 mg/ml. The data generated from initial and discovery screens performed on osteoprotegerin resulted in a formulation containing two additional additives that allowed the protein to be concentrated 10-fold without any aggregation. Using the data from the initial and discovery screens, combined with the artificial neural network, we then determined a completely new formulation. We were able to deliver this new formulation providing an additional 5 fold increase, allowing the customer to progress to the next stage of development. We were able to deliver…
  8. The HSC technology will enhance and speed research, development, and production of protein-based therapeutics, vaccines, and drugs by minimizing protein aggregation and maximizing solubility and physical stability. Additionally, the HSC technology can be used to rapidly screen crystallization conditions to identify those most likely to yield diffraction quality crystals. The power and the value of the HSC technology is ultimately derived from its ability to save months to years of time and hundreds of thousands of dollars through faster formulation of solutions for proteins.
  9. Thank you for your time. For questions, comments and additional information on the initial, discovery, and formulation screens, please feel free to email us at: info@soluble-therapeutics.com or call us at 205-420-2055.